ILD
26
8
11
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.8%
1 terminated out of 26 trials
88.9%
+2.4% vs benchmark
4%
1 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (26)
Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases
Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical Parameters
Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
Recognition of Early Pulmonary Structural Changes by Using Real-time High Fidelity Expiratory CO2 Analysis
Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease
Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD
SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection
The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease
Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis
Azithromycin and Oesophageal Function in Respiratory Disease
Edmonton Dyspnea Inventory- Validation Study
A Non-pharmacological Cough Control Therapy
Advancing Prevention of Pulmonary Fibrosis
Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy
Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild
ILD In Obese Patients With OSA
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease
Sarcopenia in Chronic Lung Diseases
Acute Effect of Whole-body Electrical Stimulation in ILD Patients
Misdiagnosis Between Interstitial Lung Disease and Cardiac Patients